Among the principal mechanisms of resistance of ALK or ROS1 positive NSCLC tumors, there are both variants in ALK or ROS1 genes (mutations or copy number gains) and ALK/ROS1 independent resistance alterations, including cKIT amplification and KRAS mutations [84,85]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.